相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors
Kyung Hae Jung et al.
CLINICAL CANCER RESEARCH (2019)
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
Georgina Long et al.
LANCET ONCOLOGY (2019)
The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma (vol 23, pg 313, 2018)
Christopher J. Ricketts et al.
CELL REPORTS (2018)
Activation of the kynurenine pathway predicts poor outcome in patients with clear cell renal cell carcinoma
Giuseppe Lucarelli et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2017)
Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD+ biosynthesis pathway and NAMPT mutation
Jun Guo et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2017)
Kynurenine Pathway of Tryptophan Metabolism: Regulatory and Functional Aspects
Abdulla A-B Badawy
INTERNATIONAL JOURNAL OF TRYPTOPHAN RESEARCH (2017)
Cancer incidence and mortality projections in the UK until 2035
C. R. Smittenaar et al.
BRITISH JOURNAL OF CANCER (2016)
Dual and Specific Inhibition of NAMPT and PAK4 By KPT-9274 Decreases Kidney Cancer Growth
Omran Abu Aboud et al.
MOLECULAR CANCER THERAPEUTICS (2016)
NAD+ salvage pathway in cancer metabolism and therapy
Barry E. Kennedy et al.
PHARMACOLOGICAL RESEARCH (2016)
Physiological Roles of Non-Neuronal NMDA Receptors
Adam D. Hogan-Cann et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2016)
Inhibiting tryptophan metabolism enhances interferon therapy in kidney cancer
Josephine F. Trott et al.
ONCOTARGET (2016)
Immunotherapy for Renal Cancer: Sequencing and Combinations
Grant D. Stewart et al.
EUROPEAN UROLOGY FOCUS (2016)
Grade-Dependent Metabolic Reprogramming in Kidney Cancer Revealed by Combined Proteomics and Metabolomics Analysis
Hiromi I. Wettersten et al.
CANCER RESEARCH (2015)
New Strategies in Renal Cell Carcinoma: Targeting the Genetic and Metabolic Basis of Disease
Ramaprasad Srinivasan et al.
CLINICAL CANCER RESEARCH (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Prognostic significance of kynurenine 3-monooxygenase and effects on proliferation, migration, and invasion of human hepatocellular carcinoma
Haojie Jin et al.
SCIENTIFIC REPORTS (2015)
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
C-STrap Sample Preparation Method-In-Situ Cysteinyl Peptide Capture for Bottom-Up Proteomics Analysis in the STrap Format
Alexandre Zougman et al.
PLOS ONE (2015)
Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues
Ivan Theate et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Suspension trapping (STrap) sample preparation method for bottom- up proteomics analysis
Alexandre Zougman et al.
PROTEOMICS (2014)
Variation in genomic landscape of clear cell renal cell carcinoma across Europe
Ghislaine Scelo et al.
NATURE COMMUNICATIONS (2014)
The Endogenous Tryptophan Metabolite and NAD+ Precursor Quinolinic Acid Confers Resistance of Gliomas to Oxidative Stress
Felix Sahm et al.
CANCER RESEARCH (2013)
IDO1 Metabolites Activate β-catenin Signaling to Promote Cancer Cell Proliferation and Colon Tumorigenesis in Mice
Ameet I. Thaker et al.
GASTROENTEROLOGY (2013)
PIK3CA mutation spectrum in urothelial carcinoma reflects cell context-dependent signaling and phenotypic outputs
R. L. Ross et al.
ONCOGENE (2013)
Tryptophan Catabolism in Cancer: Beyond IDO and Tryptophan Depletion
Michael Platten et al.
CANCER RESEARCH (2012)
Kidney Tumor Biomarkers Revealed by Simultaneous Multiple Matrix Metabolomics Analysis
Sheila Ganti et al.
CANCER RESEARCH (2012)
The NAD metabolome - a key determinant of cancer cell biology
Alberto Chiarugi et al.
NATURE REVIEWS CANCER (2012)
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
Christiane A. Opitz et al.
NATURE (2011)
Urine Metabolomic Analysis Identifies Potential Biomarkers and Pathogenic Pathways in Kidney Cancer
Kyoungmi Kim et al.
OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY (2011)
Proteomic identification of differentially expressed plasma membrane proteins in renal cell carcinoma by stable isotope labelling of a von Hippel-Lindau transfectant cell line model
Vassilis Aggelis et al.
PROTEOMICS (2009)
Immune escape as a fundamental trait of cancer: focus on IDO
G. C. Prendergast
ONCOGENE (2008)
Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma
Rainer Riesenberg et al.
CLINICAL CANCER RESEARCH (2007)
Proteomic identification of a role for the von Hippel Lindau tumour suppressor in changes in the expression of mitochondrial proteins and septin 2 in renal cell carcinoma
Rachel A. Craven et al.
PROTEOMICS (2006)
Proteomic analysis of primary cell lines identifies protein changes present in renal cell carcinoma
Rachel A. Craven et al.
PROTEOMICS (2006)
Housekeeping proteins: A preliminary study illustrating some limitations as useful references in protein expression studies
RE Ferguson et al.
PROTEOMICS (2005)
Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease
P Guidetti et al.
NEUROBIOLOGY OF DISEASE (2004)
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase
C Uyttenhove et al.
NATURE MEDICINE (2003)
Proteomic changes in renal cancer and co-ordinate demonstration of both the glycolytic and mitochondrial aspects of the Warburg effect
RD Unwin et al.
PROTEOMICS (2003)
Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase
G Frumento et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
Genetic and functional analysis of the von Hippel-Lindau (VHL) tumour suppressor gene promoter
M Zatyka et al.
JOURNAL OF MEDICAL GENETICS (2002)
Laser capture microdissection and two-dimensional polyacrylamide gel electrophoresis - Evaluation of tissue preparation and sample limitations
RA Craven et al.
AMERICAN JOURNAL OF PATHOLOGY (2002)
Contrasting effects on HIF-1α regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease
SC Clifford et al.
HUMAN MOLECULAR GENETICS (2001)
分享论文
